1	Effi	fficacy and safety of endocrine therapy after mastectomy in patients with			
2	hor	mone receptor positive breast ductal carcinoma in situ : retrospective cohort			
3	study				
4					
5	Aut	hors: Nan Niu ^{1,2,3†} , Yinan Zhang ^{1,2,3†} , Yang Bai ^{4†} , Xin Wang ⁵ , Shunchao Yan ¹ , Dong Song ⁶ , Hong			
6	Xu ⁷ ,	Tong Liu ⁸ , Bin Hua ⁹ , Yingchao Zhang ¹⁰ , Jinchi Liu ^{1,2,3} , Xinbo Qiao ^{1,2,3} , Jiaxiang Liu ⁵ , Xinyu			
7	Zhei	ng ^{11*} , Hongyi Cao ¹² *, Caigang Liu ^{1,2,3*}			
8					
9	Aut	hor Affiliations:			
10	1.	Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China;			
11	2.	Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical			
12		University, Shenyang, China;			
13	3.	Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province,			
14		Shenyang, China;			
15	4.	Department of Nursing, Shengjing Hospital of China Medical University, Shenyang 110004,			
16		China;			
17	5.	Department of Breast Surgery, National Cancer Center/National Clinical Research Center for			
18		Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical			
19		College, Beijing, China;			
20	6.	Department of Breast Surgery, the First Hospital of Jilin University, Changchun, China;			
21	7.	Department of Breast Surgery, Liaoning Cancer Hospital and Institute, Cancer Hospital of China			
22		Medical University, Shenyang, China;			
23	8.	Department of Breast Surgery, Cancer Hospital of Harbin Medical University, Harbin, China;			
24	9.	Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of			
25		Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China;			
26	10.	Department of Breast Surgery, the Second Hospital of Jilin University, Changchun, China;			
27	11.	Department of Breast Surgery, the First Affiliated Hospital of China Medical University,			
28		Shenyang, China;			

- 29 12. Department of Pathology, the First Affiliated Hospital of China Medical University and College of
- 30 Basic Medical Sciences, Shenyang, China;
- 31
- 32 * Correspondence:
- 33 Corresponding Author
- 34 Caigang Liu, MD, PhD
- 35 Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110004, China
- 36 Tel.: 86-18940254967
- 37 E-mail: liucg@sj-hospital.org
- **38** ORCID: 0000-0003-2083-235X
- 39

40 [†]: Co-first authors

41 *: Co-corresponding authors

42 Abstract

43	Background: More than half of Chinese patients with hormone receptor positive (HR+) ductal
44	carcinoma in situ (DCIS) are treated with mastectomy, and usually followed by endocrine therapy (ET).
45	Given that long-term ET can cause severe adverse effects it is important to determine the beneficial
46	effect and safety of adjuvant ET after mastectomy on the disease-free survival (DFS) and adverse
47	events in patients with HR+ DCIS.
48	Methods: To explore beneficial effect and safety of ET after mastectomy in patients with HR+ DCIS,
49	we performed a multicenter, population-based study. This retrospective study analyzed the DFS and
50	adverse events in 1037 HR+ DCIS Chinese patients with or without post-mastectomy ET from eight
51	Breast Centers between 2006-2016. The median follow-up time was 86 months.
52	Results: There were 791 DCIS patients receiving ET (ET group). Those patients were followed-up for
53	a median of 86 months (range, 60-177 months). There were 23 cases with tumor recurrence or distant
54	metastasis. There were similar 5-year DFS rates and DFS between the ET and non-ET groups, even for
55	those with high risk factors. Conversely, 37.04% of patients suffered from adverse events after ET,
56	which were significantly higher than those in the non-ET group.
57	Conclusion: ET after mastectomy did not benefit patients with HR+ DCIS for their DFS, rather
58	increased adverse events in those patients. Therefore, ET after mastectomy may not be recommended
59	for patients with HR+ DCIS, even for those with high-risk factors, such as multifocal, microinvasive

61 **Funding :** This study was supported by grants from Outstanding Scientific Fund of Shengjing

62 Hospital (201803) and Outstanding Young Scholars of Liaoning Province (2019-YQ-10).

63 Introduction:

64	Breast cancer screening in adult women has improved its early detection, increasing incidence of ductal
65	carcinoma in situ (DCIS), which currently accounts for >20% of all new breast cancers in USA(Siegel,
66	Miller, Fuchs, & Jemal, 2021) . Breast-conserving surgery (BCS) plus radiotherapy (RT) has been
67	widely used for the control of invasive cancer recurrence(Shah et al., 2016). Recent studies have shown
68	that there is an increase in the percentages of DCIS patients for unilateral and bilateral mastectomy in
69	USA, particularly for young patients(Byun, Wu, Nagar, & Gerber, 2021). There are approximate 30%
70	of DCIS patients receiving mastectomy and potential breast reconstruction, especially for those with
71	widespread, multicentric DCIS in USA(Warnberg et al., 2014; Worni et al., 2015). However, there are
72	near 60% of DCIS patients receiving mastectomy in China, particularly in the economic
73	underdeveloped regions, because they have fear of cancer recurrence (FCR) and subsequent treatment
74	costs.
75	Endocrine therapy (ET) with tamoxifen or aromatase inhibitor (AI) has been recommended for
75 76	Endocrine therapy (ET) with tamoxifen or aromatase inhibitor (AI) has been recommended for hormone receptor positive (HR+) breast cancer patients after BCS plus RT to reduce the risk of
75 76 77	Endocrine therapy (ET) with tamoxifen or aromatase inhibitor (AI) has been recommended for hormone receptor positive (HR+) breast cancer patients after BCS plus RT to reduce the risk of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence (IBTR) by National
75 76 77 78	Endocrine therapy (ET) with tamoxifen or aromatase inhibitor (AI) has been recommended for hormone receptor positive (HR+) breast cancer patients after BCS plus RT to reduce the risk of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence (IBTR) by National Comprehensive Cancer Network (NCCN)(Allred et al., 2012; Forbes et al., 2016; Ganz et al., 2016). It
75 76 77 78 79	Endocrine therapy (ET) with tamoxifen or aromatase inhibitor (AI) has been recommended for hormone receptor positive (HR+) breast cancer patients after BCS plus RT to reduce the risk of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence (IBTR) by National Comprehensive Cancer Network (NCCN)(Allred et al., 2012; Forbes et al., 2016; Ganz et al., 2016). It is notable that ET after bilateral mastectomy is not recommended for HR+ DCIS patients, who have a
75 76 77 78 79 80	Endocrine therapy (ET) with tamoxifen or aromatase inhibitor (AI) has been recommended for hormone receptor positive (HR+) breast cancer patients after BCS plus RT to reduce the risk of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence (IBTR) by National Comprehensive Cancer Network (NCCN)(Allred et al., 2012; Forbes et al., 2016; Ganz et al., 2016). It is notable that ET after bilateral mastectomy is not recommended for HR+ DCIS patients, who have a minimal risk for disease recurrence. However, ET still is being used for some HR+ DCIS patients post
75 76 77 78 79 80 81	Endocrine therapy (ET) with tamoxifen or aromatase inhibitor (AI) has been recommended for hormone receptor positive (HR+) breast cancer patients after BCS plus RT to reduce the risk of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence (IBTR) by National Comprehensive Cancer Network (NCCN)(Allred et al., 2012; Forbes et al., 2016; Ganz et al., 2016). It is notable that ET after bilateral mastectomy is not recommended for HR+ DCIS patients, who have a minimal risk for disease recurrence. However, ET still is being used for some HR+ DCIS patients post unilateral mastectomy in Western countries because ET has been thought to reduce the risk of
75 76 77 78 79 80 81 82	Endocrine therapy (ET) with tamoxifen or aromatase inhibitor (AI) has been recommended for hormone receptor positive (HR+) breast cancer patients after BCS plus RT to reduce the risk of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence (IBTR) by National Comprehensive Cancer Network (NCCN)(Allred et al., 2012; Forbes et al., 2016; Ganz et al., 2016). It is notable that ET after bilateral mastectomy is not recommended for HR+ DCIS patients, who have a minimal risk for disease recurrence. However, ET still is being used for some HR+ DCIS patients post unilateral mastectomy in Western countries because ET has been thought to reduce the risk of contralateral recurrence of invasive and pure DCIS(Byun et al., 2021). In China, ET has been widely

84 of ET for them(Mao et al., 2021). Moreover, long-term ET can cause adverse effects, particularly for

85	post-menopausal women. However, there is no report whether ET after unilateral mastectomy can
86	benefit Chinese HR+ DCIS patients for reducing contralateral recurrence of breast cancer and
87	prolonging disease-free survival (DFS) as well as its safety. Accordingly, this retrospective cohort study
88	evaluated the efficacy and safety of ET after mastectomy in the DFS and adverse events of 1037 HR+
89	DCIS patients.
90	
91	Methods
92	Subjects
93	This study was approved by the Institutional Review Board of Shengjing Hospital (approval number:
94	2020PS014K). This retrospective cohort study reviewed and analyzed the DFS and adverse events in
95	1037 HR+ DCIS patients with, or without, ET after mastectomy from December 2006 to August 2016
96	(Figure 1). The inclusion criteria included 1) Age > 18; 2) pathological diagnosis of HR+ DCIS
97	regardless of Her-2 status; 3) receiving mastectomy regardless of treatment with ET; 4) complete
98	medical records with regular post-operative follow-up at least for 5 years.
99	Data collection and statistical analysis
100	The demographic and clinical data, including age, menopausal status, diagnosis, tumor pathological
101	index, adjuvant treatments (drugs, duration), the ET-related adverse effects, tumor recurrence and
102	survival status were collected. The tumor recurrence was defined as pathologically confirmed breast
103	cancer (DCIS, invasive breast cancer) or metastatic cancers. The DFS was calculated from the
104	diagnosis to the tumor recurrence, or the last follow-up.
105	All patients were stratified, based on ET, and their demographic and clinical data were analyzed by

106 Chi-square, Fisher's exact and Wilcoxon rank sum tests where applicable. Their DFS was estimated

using Kaplan-Meier method and analyzed by the Log-rank test. The potential risk of individual factors
for the tumor recurrence was analyze by hazard ratios (HR) and 95% confidence intervals (CI). All
statistical analyses were performed by SPSS 24.0 software (SPSS, Chicago, USA). Statistical
significance was defined when a two-tailed *P*-value of <0.05.

111

112 Results

113 ET after mastectomy does not significantly alter the DFS of HR+ DCIS patients.

114 A total of 1007 HR+ DCIS patients with mastectomy were selected and their demographic and clinical 115 data, are shown in Table 1. According to ET treatment, those patients were stratified in the ET (n=791) 116 and non-ET (n=216) groups. There was no significant difference in any of the demographic and clinical 117 measures tested between these two groups. There were 23 cases (19 vs. 4 between the ET and non-ET 118 groups) with tumor recurrence, leading to 2.40% vs. 1.85% (p > 0.05, determined by Fisher exact test) 119 of tumor recurrence rate in the ET and non-ET groups throughout the 12 years post-surgical 120 observation (Table 2). There were 4 cases with invasive local recurrence, 3 with contralateral breast 121 cancer, 12 with distant metastasis in the ET group while 4 cases with distant metastases in the non-ET 122 group. Stratification analyses indicated the tumor recurrence rate was not significantly associated with 123 these measures, including high risk factors in this population (P>0.05 for all, *Table 3*). 124 There was no significantly difference in the percentages of patients with a 5-year DFS rate of 98.36% 125 vs. 99.07% between the ET and non-ET groups (P = 0.44, Figure 2A). Further analysis revealed that

126 there was also no significant difference in the percentages of patients with DFS between these

127 subgroups (P > 0.05 for all, *Figure 2B-F*), suggesting that the age, larger tumor size, positive

128 microinvasive, higher tumor grade and Ki67 levels were not associated with increased risk of worse

129 DFS in this population. Hence, ET after mastectomy did not significantly reduce the tumor recurrence

130 rate and prolong the DFS in HR+ DCIS patient.

131 The ET-related adverse effects

- 132 ET can cause musculoskeletal dysfunction, vasomotor symptoms, gynecological events, cardiovascular
- 133 events and abnormal liver-function in women, particularly in postmenopausal women. There were 551
- 134 patients receiving tamoxifen, 223 with AI and others beginning with tamoxifen and later switching to
- AI. Analysis of adverse events in both groups revealed that 37.04% of patients in the ET group
- 136 developed at least one adverse event, including bone fracture or endometrial cancer (n=4 each), while
- 137 15.28% of cases with these events in the non-ET group. There were 14.54% of patients with
- 138 musculoskeletal dysfunctions, such as arthralgia, joint stiffness, osteoporosis or myalgia in the ET
- 139 group and the percentages of some adverse events tested in the ET group were significantly higher than
- 140 that in the non-ET group in this population (*Figure 3*). Adverse events between TAM and AI in the ET
- 141 group are shown in *Table 4*.
- 142 Therefore, ET after mastectomy was associated with increased risk for development of different types143 of adverse effects in patients with HR+ DCIS.
- 144

145 Discussion

- Therapeutic strategies for HR+ DCIS, including mastectomy or BCS plus RT, have achieved a similarly high survival rate in patients(Mannu et al., 2020; Narod, Iqbal, Giannakeas, Sopik, & Sun, 2015). Although ET after BCS plus RT is recommended for patients with HR+ DCIS, and benefits for those with positive surgical margin(Allred et al., 2012; Forbes et al., 2016; Ganz et al., 2016; Wapnir et
- al., 2011), many HR+ DCIS Asian patients chose mastectomy and received ET(Mao et al., 2021; Worni

151	et al., 2015). In the present study, 78.55 % of HR+ DCIS patients were treated with post-mastectomy
152	ET. More importantly, we found that there was no significant difference in 5-year DFS rate and tumor
153	recurrence rate in HR+ DCIS patients regardless of ET, even in those with high risk factors for tumor
154	recurrence. To the best of our knowledge, this was the first report on the efficacy of ET after
155	mastectomy in the DFS of Chinese HR+DCIS patients and these novel findings clearly indicated that
156	ET after mastectomy did not prolong the DFS of HR+ DCIS patients.
157	Long-term ET can cause multiple adverse effects, affecting the life-quality of patients. Indeed, 37.04%
158	of patients suffered from adverse events following ET. Quantitative analysis revealed that the
159	percentages of patients with musculoskeletal dysfunction, gynaecological events and abnormal
160	liver-function, but not vasomotor symptoms and cardiovascular events in the ET group were
161	significantly higher than that in the non-ET group of patients. The increased percentages of patients
162	with these clinical symptoms demonstrated that long-term ET caused multiple adverse effects in HR+
163	DCIS patients after mastectomy. Given that the majority of HR+ DCIS patients chose mastectomy with
164	a long DFS and ET after mastectomy did not prolong their DFS, rather significantly increased
165	ET-related adverse effects in those patients, our findings suggest that ET may be decreased for its dose
166	and duration or completely avoided for HR+ DCIS patients following mastectomy to improve their
167	life-quality.
168	Several limitations of our study include its retrospective nature and the length of follow-up. To fully
169	evaluate the differences in treatment, longer follow-up and randomized trials are necessary.
170	

171 Conclusions

172 ET after mastectomy did not prolong the DFS of HR+ DCIS patients, rather increased adverse effects.

173 Our findings suggest not providing ET for HR+ DCIS patients after mastectomy.

174 Competing interests

175 Caigang Liu: Senior editor, *eLife*. The other authors declare that no competing interests exist.

176 Funding

Funder	Grant reference number	Author		
Outstanding Young Scholars of	2019-YQ-10	Caigang Liu		
Liaoning Province				
Outstanding Scientific Fund of	201803	Caigang Liu		
Shengjing Hospital				
The funders had no role in study design, data collection and interpretation, or the decision to submit				
the work for publication.				

177 Author contributions

178	Nan Niu, Data curation, Formal analysis, Writing - original draft preparation, Writing - review &
179	editing; Yinan Zhang, Investigation, Data curation, Formal analysis; Yang Bai, Investigation, Data
180	curation; Xin Wang, Investigation, Data curation; Shunchao Yan, Writing - original draft preparation;
181	Dong Song, Investigation, Data curation; Hong Xu, Investigation, Data curation; Tong Liu,
182	Investigation, Data curation; Bin Hua, Investigation, Data curation; Yingchao Zhang, Investigation,
183	Data curation; Jinchi Liu, Methodology, Formal analysis; Xinbo Qiao, Methodology, Formal analysis;
184	Jiaxiang Liu, Investigation, Data curation; Xinyu Zheng, Conceptualization, Supervision, Project
185	administration; Hongyi Cao, Investigation, Data curation, Formal analysis; Caigang Liu,
186	Conceptualization, Funding acquisition, Project administration, Writing - review and editing.

187 Data availability

188 All data generated or analysed during this study are included in the manuscript and supporting files.

189 Author ORCIDs

- 190 Nan Niu <u>https://orcid.org/0000-0002-8206-941X</u>
- 191 Caigang Liu http://orcid.org/0000-0003-2083-235X

192 References

194 Allred, D. C., Anderson, S. J., Paik, S., Wickernam, D. L., Nagtegaal, I. D., Sv	Swain, S.	S. M.,
--	-----------	--------

- 195 Wolmark, N. (2012). Adjuvant tamoxifen reduces subsequent breast cancer in women
- 196 with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP
- 197 protocol B-24. *J Clin Oncol, 30*(12), 1268-1273. doi:10.1200/JCO.2010.34.0141
- Byun, D., Wu, S., Nagar, H., & Gerber, N. (2021). Ductal Carcinoma in Situ in Young Women:
- 199 Increasing Rates of Mastectomy and Variability in Endocrine Therapy Use. Annals of
- 200 *surgical oncology, 28*(11), 6083-6096. doi:10.1245/s10434-021-09972-2
- 201 Forbes, J. F., Sestak, I., Howell, A., Bonanni, B., Bundred, N., Levy, C., . . . Cuzick, J. (2016).
- 202 Anastrozole versus tamoxifen for the prevention of locoregional and contralateral
- 203 breast cancer in postmenopausal women with locally excised ductal carcinoma in situ
- 204 (IBIS-II DCIS): a double-blind, randomised controlled trial. The Lancet, 387(10021),
- 205 866-873. doi:10.1016/s0140-6736(15)01129-0
- 206 Ganz, P. A., Cecchini, R. S., Julian, T. B., Margolese, R. G., Costantino, J. P., Vallow, L. A., ...
- 207 Wolmark, N. (2016). Patient-reported outcomes with anastrozole versus tamoxifen for
- 208 postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus
- 209 radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. *The*
- 210 Lancet, 387(10021), 857-865. doi:10.1016/s0140-6736(15)01169-1
- 211 Mannu, G. S., Wang, Z., Broggio, J., Charman, J., Cheung, S., Kearins, O., . . . Darby, S. C.
- 212 (2020). Invasive breast cancer and breast cancer mortality after ductal carcinoma in
- situ in women attending for breast screening in England, 1988-2014: population based

214	observational cohort study. BMJ, 369, m1570. doi:10.1136/bmj.m1570
215	Mao, G., Shi, X., Wang, X., Zhang, X., Chen, X., Ma, J., Guo, X. (2021). Clinicopathological
216	Characteristics of Breast Ductal Carcinoma In Situ: An Analysis of Chinese Population
217	of 617 Patients. Journal of oncology, 2021, 8854418. doi:10.1155/2021/8854418
218	Narod, S. A., Iqbal, J., Giannakeas, V., Sopik, V., & Sun, P. (2015). Breast Cancer Mortality
219	After a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncology, 1(7).
220	doi:10.1001/jamaoncol.2015.2510
221	Shah, C., Wobb, J., Manyam, B., Kundu, N., Arthur, D., Wazer, D., Vicini, F. (2016).
222	Management of Ductal Carcinoma In Situ of the Breast: A Review. JAMA Oncol, 2(8),
223	1083-1088. doi:10.1001/jamaoncol.2016.0525
224	Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer Statistics, 2021. CA
225	<i>Cancer J Clin, 71</i> (1), 7-33. doi:10.3322/caac.21654
226	Wapnir, I. L., Dignam, J. J., Fisher, B., Mamounas, E. P., Anderson, S. J., Julian, T. B.,
227	Wolmark, N. (2011). Long-term outcomes of invasive ipsilateral breast tumor
228	recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for
229	DCIS. <i>J Natl Cancer Inst, 103</i> (6), 478-488. doi:10.1093/jnci/djr027
230	Warnberg, F., Garmo, H., Emdin, S., Hedberg, V., Adwall, L., Sandelin, K., Holmberg, L.
231	(2014). Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in
232	situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol, 32(32),
233	3613-3618. doi:10.1200/JCO.2014.56.2595
234	Worni, M., Akushevich, I., Greenup, R., Sarma, D., Ryser, M. D., Myers, E. R., & Hwang, E. S.
235	(2015). Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. ${\cal J}$ 13

236 Natl Cancer Inst, 107(12), djv263. doi:10.1093/jnci/djv263

238 Figure legends:

239 Figure 1. Flow chart of the study.

240 Figure 2. The disease-free survival of HR+ DCIS patients with or without post mastectomy ET.

- 241 Kaplan-Meier analysis indicated that there was no significant difference in the DFS of HR+ DCIS patients between
- those with and without post-mastectomy ET. (A) There was no significant difference in the DFS of HR+ DCIS
- 243 patients with age < 50, (B) a larger tumor, (C) positive microinvasive, (D) higher tumor grade, (E) higher Ki67
- 244 level, (F) between those with and without post-mastectomy ET. HR, hormone receptor; DCIS, ductal carcinoma in
- situ; ET, endocrine therapy; DFS, disease-free survival.
- Figure 3. The frequency of patients with adverse effects between the ET and non-ET groups.
- 247 Data are expressed as % of cases with adverse events and real case numbers labeled and analyzed by Chi-squared
- 248 test. *P<0.05, **P<0.01, ***P<0.001. ET, endocrine therapy.

	ET (<i>N</i> =791)	Non ET (<i>N</i> =216)	p-Value
Age (n, %)			0.134
≤50	448 (57%)	110 (51%)	
>50	343 (43%)	106 (49%)	
Tumor size (<i>n</i> , %)			0.839
≤20mm	459 (58%)	127 (59%)	
>20mm	332 (42%)	89 (41%)	
Microinvasive (n, %)			0.322
Yes	128 (16%)	29 (13%)	
No	663 (84%)	187 (87%)	
Tumor grade (<i>n,</i> %)			0.190
-	565 (71%)	164 (76%)	
III	226(29%)	52 (24%)	
Ki67 (n, %)			0.071
≥15%	279 (35%)	62 (29%)	
<15%	512 (65%)	154 (71%)	
Multifocal (n, %)			0.310
Yes	64 (8%)	13 (6%)	
No	727 (92%)	203 (94%)	

249 Table 1. The demographic and clinical characteristics of patients.

250 Notes: Data are n (%). ET, endocrine therapy.

252 Table 2. Tumor recurrence rates in patients with HR+ DCIS after mastectomy.

Tumor Recurrence	ET (<i>N</i> =19)	Non ET (<i>N</i> =4)
Invasive Local Recurrence	4 (21%)	0 (0%)
Contralateral Breast Cancer	3 (16%)	0 (0%)
Distant Metastasis		
Bone	6 (32%)	1 (25%)
Liver	2 (11%)	2 (50%)
Lung	1 (5%)	0 (0%)
Brain	1 (5%)	0 (0%)
Abdominal Cavity	1 (5%)	1 (25%)
Lymph nodes	1 (5%)	0 (0%)

253 Notes: Data are n (%). HR, hormone receptor; DCIS, ductal carcinoma in situ; ET, endocrine therapy.

255 Table 3. Stratification analysis of tumor recurrence rates in patients with HR+ DCIS after

256 mastectomy.

ET (<i>N</i> =791)	Non ET (<i>N</i> =216)	HR (95% CI)	p-Value
19 (791)	4 (216)	1.30 (0.48 to 3.52)	0.64
12 (448)	1 (110)	2.91 (0.74 to 11.47)	0.28
7 (343)	3 (106)	0.75 (0.18 to 3.17)	0.67
6 (459)	2 (127)	0.82 (0.15 to 4.44)	0.81
13 (332)	2 (89)	1.75 (0.51 to 6.04)	0.45
8 (128)	0 (29)	3.48 (0.60 to 20.02)	0.16
11 (663)	4 (187)	0.76 (0.22 to 2.59)	0.64
10 (565)	0 (164)	3.64 (0.82 to 16.06)	0.09
9 (226)	4 (52)	0.51 (0.13 to 2.07)	0.26
7 (279)	1 (62)	0.88 (0.09 to 8.29)	0.67
12 (512)	3 (154)	1.42 (0.46 to 4.38)	0.74
3 (64)	0 (13)	3.34 (0.17 to 67.46)	0.43
16 (727)	4 (203)	1.11 (0.38 to 3.22)	0.85
	ET (N=791) 19 (791) 12 (448) 7 (343) 6 (459) 13 (332) 8 (128) 11 (663) 10 (565) 9 (226) 7 (279) 12 (512) 3 (64) 16 (727)	ET (N=791)Non ET (N=216)19 (791)4 (216)12 (448)1 (110)7 (343)3 (106)7 (343)3 (106)6 (459)2 (127)13 (332)2 (89)8 (128)0 (29)11 (663)4 (187)10 (565)0 (164)9 (226)4 (52)7 (279)1 (62)12 (512)3 (154)3 (64)0 (13)16 (727)4 (203)	ET (N=791)Non ET (N=216)HR (95% Cl)19 (791)4 (216)1.30 (0.48 to 3.52)12 (448)1 (110)2.91 (0.74 to 11.47)7 (343)3 (106)0.75 (0.18 to 3.17)7 (343)3 (106)0.75 (0.18 to 3.17)6 (459)2 (127)0.82 (0.15 to 4.44)13 (332)2 (89)1.75 (0.51 to 6.04)8 (128)0 (29)3.48 (0.60 to 20.02)11 (663)4 (187)0.76 (0.22 to 2.59)10 (565)0 (164)3.64 (0.82 to 16.06)9 (226)4 (52)0.51 (0.13 to 2.07)7 (279)1 (62)0.88 (0.09 to 8.29)12 (512)3 (154)1.42 (0.46 to 4.38)3 (64)0 (13)3.34 (0.17 to 67.46)16 (727)4 (203)1.11 (0.38 to 3.22)

257 Notes: HR, hormone receptor; DCIS, ductal carcinoma in situ; ET, endocrine therapy.

259 Table 4. Adverse events between TAM and AI in the ET group.

Adverse Events	TAM (<i>N</i> =551)	AI (<i>N</i> =223)
Total	212 (38%)	76 (34%)
Musculoskeletal Symptoms	61 (11%)	52 (23%)
Vasomotor Symptoms	42 (8%)	12 (5%)
Gynecological Events	113 (21%)	5 (2%)
Cardiovascular Events	26 (5%)	12 (5%)
Abnormal Liver-function	10 (2%)	4 (2%)

260

Notes: TAM, tamoxifen; AI, aromatase inhibitor; ET, endocrine therapy.





